Although PPARγ agonists have effective immunoregulatory capacity in many autoimmune diseases and transplant rejection animal models, the side effects of conventional thiazolidinedione drugs (TZD) have been reported in recent clinical studies [12]. Here, PPARG is linked to autoimmune disease.